New drug plus bevacizumab versus bevacizumab alone for advanced ovarian cancer

Plain-English translation of NCT07851025 on ClinicalTrials.gov ↗ · Source last updated October 2026 · Translation generated October 2026 · How we translate trials

Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.

What is this trial?

This trial is testing whether , a new cancer-fighting medication, works better when combined with (a drug already used to treat ovarian cancer) compared to alone. The study focuses on people with advanced ovarian cancer who have completed initial chemotherapy and don't have a specific genetic change called HRD. Researchers want to see if adding this medication helps people stay cancer-free longer.

Currently, alone is used as maintenance therapy (ongoing treatment after initial chemotherapy) for certain ovarian cancer patients, but the cancer often comes back. This trial is testing whether the new treatment could work better by slowing or preventing the cancer's return in people who aren't eligible for other newer therapies.

Do you qualify?

You likely qualify if…

you have been diagnosed with advanced stage epithelial ovarian cancer (stage III or IV), fallopian tube cancer, or peritoneal cancer
your cancer has not gotten worse after completing 6 to 8 cycles of platinum-based chemotherapy combined with bevacizumab
your tumor has been tested and confirmed to be HRD-negative (meaning it doesn't have a specific genetic marker)
you had surgery to remove as much cancer as possible, or your cancer cannot be surgically removed
a sample of your tumor tissue is available for testing

You likely don't qualify if…

you have a history of severe lung inflammation (ILD or pneumonitis) that required steroids or extra oxygen
you currently have active lung inflammation or a suspected lung problem that hasn't been ruled out
you have a non-healing wound, active ulcer, or bone fracture
you have an active bowel obstruction
you have previously received other folate receptor alpha-targeted therapy or certain types of antibody-drug conjugates

What participation looks like

If you join this trial, you will be randomly assigned to receive either the new medication plus or alone, given intravenously (through an IV). You'll have regular visits to receive your treatment and be monitored for how well it's working and any side effects. The trial involves about 950 participants, and you'd continue treatment as long as your cancer doesn't get worse and you're tolerating the medication well.

AI-generated summary from trial data · Oct 12, 2026 · Not medical advice

Trial locations(186 sites)

United States

Research Site, Tampa, Florida

Research Site, Baltimore, Maryland

Research Site, Billings, Montana

Research Site, Cleveland, Ohio

Argentina

Research Site, Buenos Aires